Clinical trials: Multiple Dose
Excessive Daytime Sleepiness
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
- Trial name
- NCT07082829
- Testing
- ORX142 Tablets
- Where
- 3 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
Diabetes, Diabetes Mellitus, Type 2
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01572753
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Parkinson Disease
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects
- Trial name
- NCT04625361
- Testing
- HEC122505MsOH
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Tuberculosis
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
The purpose of this study is to determine the safety and tolerability of PA-824 when given with a single dose of midazolam, and to determine whether PA-824 inhibits CYP3A to a clinically important degree as measured by the effect…
- Trial name
- NCT01768273
- Testing
- Midazolam, PA-824
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin
Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at steady state after a multiple oral administration and…
- Trial name
- NCT04245046
- Testing
- Candesartan, Amlodipine, Atorvastatin
- Where
- Jordan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Midas Pharma GmbH
Healthy
A Phase I Study of LX22001 for Injection in Healthy Subjects
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
- Trial name
- NCT06561542
- Testing
- LX22001 for Injeciton, Tegoprazan tablet, Esomeprazole sodium for injection
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Healthy Volunteer Study
Phase 1 BIO 300 Oral Suspension
This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug…
- Trial name
- NCT06741345
- Testing
- BIO 300 Oral Suspension
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Humanetics Corporation
Psoriasis Vulgaris
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral…
- Trial name
- NCT00833872
- Testing
- LEO 22811
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Immune System and Related Disorders, Immune System Diseases
Study of Cannabidiol (CBD) in Healthy Volunteers
This was a prospective, single-centre, open label, randomized, two-arm, parallel design study to evaluate the effect of four-weeks consumption of active study product on primary endpoint in healthy adults
- Trial name
- NCT06286839
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- NextEvo Inc.
Healthy
A Study to Evaluate the Safety of K-755 in Healthy Volunteers
This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.
- Trial name
- NCT03414294
- Testing
- K-755 Part A (SAD), K-755 Part B (MAD), K-755 Part C (FE)
- Where
- Australia
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Kowa Company, Ltd.
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW243040 in Healthy Participants
This is a Phase I, randomized, double-blind, placebo-controlled, single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HW243040 in healthy participants.
- Trial name
- NCT07841522
- Testing
- HW243040
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Diabetes Mellitus, Type 2
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)
This study is to characterize the pharmacokinetics, safety, tolerability, and pharmacodynamics of single and multiple oral doses (SD, MD) of ertugliflozin (PF-04971729, MK-8835) in Japanese healthy participants.
- Trial name
- NCT01223339
- Testing
- Ertugliflozin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study
The goal of this clinical trial is to learn the comparative pharmacokinetic parameters between the test product and the Reference listed drug in healthy female volunteers The main question[s] it aims to answer are: To assess the…
- Trial name
- NCT06074757
- Testing
- Fulvestrant injection
- Where
- Jordan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Healthy Volunteers
Pharmacokinetics of PN-235 in Healthy Volunteers
This Phase 1 study is designed to determine the safety, tolerability and pharmacokinetics of PN-235 in healthy volunteers. The study will be conducted in three parts: Part 1 is a single ascending dose study, Part 2 is multiple…
- Trial name
- NCT04621630
- Testing
- PN-235
- Where
- Australia
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Protagonist Therapeutics, Inc.
Healthy, Overweight
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B, C) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and…
- Trial name
- NCT06309667
- Testing
- PG-102(MG12)
- Where
- South Korea
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- ProGen. Co., Ltd.
Fungal Infection
Safety and Pharmacokinetics of Rezafungin
This is a Phase 1, double-blind, placebo-controlled trial in three parts. A single ascending dose (SAD) study in six cohorts receiving a single subcutaneous (SC) dose of 1, 10, 30, 60, 100, or 200 mg of rezafungin; a multiple…
- Trial name
- NCT04117607
- Testing
- Rezafungin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of…
- Trial name
- NCT05219253
- Testing
- HZ/su
- Where
- 9 sites in India
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer. The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT06554639
- Testing
- MK-5684, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.